Literature DB >> 8049205

NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.

B J Denny1, R T Wheelhouse, M F Stevens, L L Tsang, J A Slack.   

Abstract

The hypothesis that the antitumor prodrug temozolomide is ring-opened to MTIC which then further breaks down to a reactive diazonium ion at guanine-rich sequences in DNA has been probed by NMR spectroscopy and computational techniques. Temozolomide is stable at acid pH but decomposes to MTIC at pH > 7; in contrast, MTIC is stable at alkaline pH values but rapidly fragments in a methylating mode at pH < 7. The proximate methylating agent is the reactive methyldiazonium species. Runs of guanine residues represent an accessible nucleophilic microenvironment in DNA site-specific conversion of the prodrug temozolomide to MTIC possibly via an activated water molecule in the major groove. Molecular modeling of the structure of temozolomide indicates that the prodrug can make a favorable noncovalent encounter with DNA. The known structure-activity relationships as well as the biological and clinical properties of temozolomide can be interpreted in terms of this model.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8049205     DOI: 10.1021/bi00197a003

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  108 in total

1.  Replication of the 2,6-diamino-4-hydroxy-N(5)-(methyl)-formamidopyrimidine (MeFapy-dGuo) adduct by eukaryotic DNA polymerases.

Authors:  Plamen P Christov; Kinrin Yamanaka; Jeong-Yun Choi; Kei-ichi Takata; Richard D Wood; F Peter Guengerich; R Stephen Lloyd; Carmelo J Rizzo
Journal:  Chem Res Toxicol       Date:  2012-07-06       Impact factor: 3.739

Review 2.  Molecular mechanism of adenomatous polyposis coli-induced blockade of base excision repair pathway in colorectal carcinogenesis.

Authors:  Satya Narayan; Ritika Sharma
Journal:  Life Sci       Date:  2015-09-01       Impact factor: 5.037

3.  The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain.

Authors:  Sadhana Jackson; Nicole M Anders; Antonella Mangraviti; Teresia M Wanjiku; Eric W Sankey; Ann Liu; Henry Brem; Betty Tyler; Michelle A Rudek; Stuart A Grossman
Journal:  J Neurooncol       Date:  2015-12-01       Impact factor: 4.130

4.  MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.

Authors:  Manik Chahal; Yaoxian Xu; David Lesniak; Kathryn Graham; Konrad Famulski; James G Christensen; Manish Aghi; Amanda Jacques; David Murray; Siham Sabri; Bassam Abdulkarim
Journal:  Neuro Oncol       Date:  2010-02-23       Impact factor: 12.300

5.  Acquisition of temozolomide chemoresistance in gliomas leads to remodeling of mitochondrial electron transport chain.

Authors:  Claudia R Oliva; Susan E Nozell; Anne Diers; Samuel G McClugage; Jann N Sarkaria; James M Markert; Victor M Darley-Usmar; Shannon M Bailey; G Yancey Gillespie; Aimee Landar; Corinne E Griguer
Journal:  J Biol Chem       Date:  2010-09-24       Impact factor: 5.157

6.  Histone Methylation by Temozolomide; A Classic DNA Methylating Anticancer Drug.

Authors:  Tieli Wang; Amanda J Pickard; James M Gallo
Journal:  Anticancer Res       Date:  2016-07       Impact factor: 2.480

Review 7.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

8.  The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.

Authors:  Tor-Christian Aase Johannessen; Lars Prestegarden; Amra Grudic; Monika E Hegi; Berit Bølge Tysnes; Rolf Bjerkvig
Journal:  Neuro Oncol       Date:  2012-12-20       Impact factor: 12.300

9.  Temozolomide-mediated DNA methylation in human myeloid precursor cells: differential involvement of intrinsic and extrinsic apoptotic pathways.

Authors:  Haiyan Wang; Shanbao Cai; Aaron Ernstberger; Barbara J Bailey; Michael Z Wang; Wenjing Cai; W Scott Goebel; Magdalena B Czader; Colin Crean; Attaya Suvannasankha; Inna Shokolenkoc; Glenn L Wilson; Arthur R Baluyut; Lindsey D Mayo; Karen E Pollok
Journal:  Clin Cancer Res       Date:  2013-03-27       Impact factor: 12.531

Review 10.  Small-molecule inhibitors of proteins involved in base excision repair potentiate the anti-tumorigenic effect of existing chemotherapeutics and irradiation.

Authors:  April M Reed; Melissa L Fishel; Mark R Kelley
Journal:  Future Oncol       Date:  2009-06       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.